000	00000nam 2200000zi 4500
001	9.937142
003	CaOODSP
005	20240612114835
006	m     o  d f
007	cr |n|||||||||
008	240419e20180620onc     o    f|0| 0 eng d
040	|aCaOODSP|beng|erda|cCaOODSP
043	|an-cn---
086	1 |aH14-604/2018E-PDF
245	00|aAudit of the Biologics and Radiopharmaceutical Drugs Program at Health Canada, June 2018.
264	1|a[Ottawa] : |bHealth Canada and the Public Health Agency of Canada = Santé Canada et l'Agence de la santé publique du Canada, |cJune 20, 2018.
300	|a1 online resource (27 unnumbered pages) + |emanagement response and action plan (5 unnumbered pages)
336	|atext|btxt|2rdacontent
337	|acomputer|bc|2rdamedia
338	|aonline resource|bcr|2rdacarrier
500	|aIssued also in French under title: Audit du programme des produits biologiques et radiopharmaceutiques de Santé Canada, juin 2018.
500	|a"Final report presented to the Departmental Audit Committee, June 20, 2018."
520	|a"We examined the management control framework related to the Biologics and Radiopharmaceutical Drugs Program (BRDP or the Program). The audit focused on governance, risk management, and internal controls..."--Executive Summary, page [4].
610	10|aCanada. |bHealth Canada|xAuditing.
610	20|aPublic Health Agency of Canada|xAuditing.
650	0|aBiologicals|zCanada|xAuditing.
710	1 |aCanada. |bHealth Canada, |eissuing body.
710	2 |aPublic Health Agency of Canada, |eissuing body.
775	08|tAudit du programme des produits biologiques et radiopharmaceutiques de Santé Canada, juin 2018.|w(CaOODSP)9.937144
856	40|qPDF|s603 KB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/H14-604-2018-eng.pdf|zFinal report
856	40|qPDF|s208 KB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/H14-604-2018-1-eng.pdf|zManagement Response and Action Plan
856	41|qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/corporate/transparency/corporate-management-reporting/internal-audits/biologics-pharmaceutical-drugs-program.html|zFinal report